Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?

Most patients with non‐small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations, such as deletions in exon 19 or the L858R mutation in exon 21, respond dramatically to EGFR tyrosine kinase inhibitors (EGFR‐TKI), and their sensitivities to various EGFR‐TKI hav...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Sci
Auteurs principaux: Banno, Eri, Togashi, Yosuke, Nakamura, Yu, Chiba, Masato, Kobayashi, Yoshihisa, Hayashi, Hidetoshi, Terashima, Masato, de Velasco, Marco A., Sakai, Kazuko, Fujita, Yoshihiko, Mitsudomi, Tetsuya, Nishio, Kazuto
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2016
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4982590/
https://ncbi.nlm.nih.gov/pubmed/27240419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12980
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires